Wyrick Robbins Helps PPD Close Acquisition by Carlyle and Hellman & Friedman
RALEIGH, NC—Wyrick Robbins served as lead counsel to its long-time client, Pharmaceutical Product Development, Inc. (PPD), in connection with the company’s acquisition by affiliates of The Carlyle Group and Hellman & Friedman, which closed today.
The merger is an all-cash transaction valued at $3.9 billion. According to The Wall Street Journal, this was the third largest private equity transaction in the U.S. this year.
“We are honored to serve as counsel to our long-time client PPD in this significant transaction,” said Wyrick Robbins partner Donald R. Reynolds, who was assisted in this representation by, among others,James L.S. Cobb (Partner), Amy E. Davis (Associate), and Rishi J. Kotiya (Associate). All are members of the firm’s Capital Markets/M&A Practice Group in Raleigh, North Carolina.
About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. PPD’s clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visitwww.ppdi.com.
About Wyrick Robbins
Wyrick Robbins is an entrepreneurial law firm with a focus on growth-oriented businesses. The firm handles financial and corporate transactions and complex commercial litigation as well as other legal needs of dynamic companies. In addition, Wyrick Robbins lawyers serve as trusted advisors to founders, investors, directors and management.
For more information:
Jennifer Herendeen
jherendeen@wyrick.com
919.781.4000